2017
DOI: 10.3892/ol.2017.5725
|View full text |Cite
|
Sign up to set email alerts
|

Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development

Abstract: There is individual variation in the course of disease development and response to therapy of patients with chronic lymphocytic leukemia (CLL). Novel treatment options for CLL include a new generation of purine analogs, antibodies and inhibitors of specific cell signaling pathways, which typically induce apoptosis or necrosis. A prospective analysis of patient blood samples revealed that a combination of four tests allowed the most appropriate and effective type of treatment to be selected prior to drug admini… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
12
0
1

Year Published

2019
2019
2021
2021

Publication Types

Select...
5

Relationship

3
2

Authors

Journals

citations
Cited by 6 publications
(15 citation statements)
references
References 31 publications
2
12
0
1
Order By: Relevance
“…Our findings reveal significant differences in the response to anticancer agents among leukemic patients, as noticed in previous studies (8,14,15). Moreover, our results show that the comparison of cell viability, apoptosis rate, and the level of necrosis underline the importance of proper anticancer agent dose selection to avoid the occurrence of a high necrosis level that could transform in vivo into inflammation.…”
Section: Discussionsupporting
confidence: 86%
See 4 more Smart Citations
“…Our findings reveal significant differences in the response to anticancer agents among leukemic patients, as noticed in previous studies (8,14,15). Moreover, our results show that the comparison of cell viability, apoptosis rate, and the level of necrosis underline the importance of proper anticancer agent dose selection to avoid the occurrence of a high necrosis level that could transform in vivo into inflammation.…”
Section: Discussionsupporting
confidence: 86%
“…It must be stated that these combined results are difficult to compare with those of each single patient. It is important to note that the results for patients 15, 16 or 17 presented here indicate that the median results presented in scientific papers usually provide incorrect recommendations (13–15) concerning patient resistance/sensitivity to anticancer agents, and these would not be effective in treating patient no. 16.…”
Section: Resultsmentioning
confidence: 81%
See 3 more Smart Citations